The renal effects of SGLT2 inhibitors and a mini-review of the literature

Therapeutic Advances in Endocrinology and Metabolism

Volumn 7, Issue 5-6, 2016, Pages 212-228

  Andrianesis, Vasileios ^a   Glykofridi, Spyridoula ^b   Doupis, John ^c  

^a ATHENS NAVAL HOSPITAL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c Division of Diabetes Iatriko Paleou Falirou Medical Center   (Greece)

Author keywords

albuminuria; glucosuria; hyperfiltration; renal impairment; renoprotection; SGLT transporters; SGLT2 inhibitors; tubulointerstitial fibrosis; type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLUCOSE TRANSPORTER; HEMOGLOBIN A1C; IPRAGLIFLOZIN; LOSARTAN; LUSEOGLIFLOZIN; PHLORIZIN; PLACEBO; REMOGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN;

BLADDER CANCER; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN SENSITIVITY; KETOACIDOSIS; KETONURIA; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; LIPOLYSIS; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSMOTIC DIURESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLLAKISURIA; PRIORITY JOURNAL; RENAL DIABETES; RENAL PROTECTION; REVIEW; URINARY TRACT INFECTION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 85006446501     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018816676239     Document Type: Review

References (120)

1. Abdul-Ghani M., DeFronzo R., (2008) Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 14: 782–790.
2. Abdul-Ghani M., DeFronzo R., (2014) Lowering plasma glucose concentration by inhibiting renal sodium-glucose co-transport. J Intern Med 276: 352–363. DOI:10.1111/joim.12244.
3. ™ (dapagliflozin) now approved in European Union for treatment of type 2 diabetes. Available at: https://www.astrazeneca.com/media-centre/press-releases/2012/FORXIGA-dapagliflozin-now-approved-in-European-Union-for-treatment-of-type-2-diabetes-14112012.html#! (accessed 28 October 2016).
4. Augustin R., (2010) The protein family of glucose transport facilitators: it’s not only about glucose after all: critical review. IUBMB Life 62: 315–333.
5. Bailey C., Gross J., Pieters A., Bastien A., List J., (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223–2233.
6. Barfuss D., Schafer J., (1981) Differences in active and passive glucose transport along the proximal nephron. Am J Physiol 240: F322–F332.
7. Barnett A., Mithal A., Manassie J., Jones R., Rattunde H., Woerle H.. (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 369–384.
8. Berhan A., Barker A., (2013) Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocrine Disorders 13: 1–11.
9. Bolinder J., Ljunggren Ö., Kullberg J., Johansson L., Wilding J., Langkilde A.. (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97: 1020–1031.
10. Bonner C., Kerr-Conte J., Gmyr V., Queniat G., Moerman E., Thévenet J.. (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21: 512–517.
11. Brenner B., Hostetter T., Olson J., Rennke H., Venkatachalam M., (1981) The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy. Acta Endocrinol Suppl (Copenh) 242: 7–10.
12. Cherney D., Konvalinka A., Zinman B., Diamandis E., Soosaipillai A., Reich H.. (2009) Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care 32: 91–93.
13. Cherney D., Miller J., Scholey J., Bradley T., Slorach C., Curtis J.. (2008) The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 57: 688–695.
14. Cherney D., Perkins B., Soleymanlou N., Maione M., Lai V., Lee A.. (2014) The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation 129: 587–597. DOI:10.1161/CIRCULATIONAHA.113.005081.
15. Cherney D., Reich H., Jiang S., Har R., Nasrallah R., Hebert R.. (2012) Hyperfiltration and the effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 303: R710–R718.
16. De Marchi S., Cecchin E., Basile A., Proto G., Donadon W., Schinella D.. (1983) Is renal glycosuria a benign condition? Proc Eur Dial Transplant Assoc 20: 681–685.
17. DeFronzo R., (2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 273–295.
18. DeFronzo R., Davidson J., Del Prato S., (2012) The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14: 5–14.
19. Devineni D., Morrow L., Hompesch M., Skee D., Vandebosch A., (2012) Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 14: 539–545.
20. Ehrenkranz J., Lewis N., Kahn C., Roth J., (2005) Phlorizin: a review. Diabetes Metab Res Rev 21: 31–38.
21. Farber S., Berger E., Earle D., (1951) Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30: 125–129.
22. Ferrannini E., Berk A., Hantel S., Pinnetti S., Hach T., Woerle H.. (2013a) Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36: 4015–4021.
23. Ferrannini E., Muscelli E., Frascerra S., Baldi S., Mari A., Heise T.. (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124: 499–508.
24. Ferrannini E., Ramos S., Salsali A., Tang W., List J., (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double- blind, placebo-controlled, phase III trial. Diabetes Care 33: 2217–2224.
25. Ferrannini E., Veltkamp S., Smulders R., Kadokura T., (2013b) Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 36: 1260–1265.
26. Fitchett D., Zinman B., Wanner C., Lachin J., Hantel S., Salsali A.. (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 26. pii: ehv728.
27. Fonseca V., Ferrannini E., Wilding J., Wilpshaar W., Dhanjal P., Ball G.. (2013) Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications 27: 268–267.
28. Gerich J., (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27: 136–142.
29. Gilbert R., Cooper M., (1999) The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56: 1627–1637.
30. Guyton A., Hall J., (2006) Chapter 27: Urine formation by the kidneys: II tubular processing of the glomerular filtrate. In Guyton A, Hall J, (Ed.), Textbook of Medical Physiology (11th ed.; pp. 327–347). Philadelphia, Pennsylvania: Elsevier Saunders.
31. Hansen H., Jelsing J., Hansen C., Hansen G., Vrang N., Mark M.. (2014) The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male Zucker diabetic fatty rat. J Pharmacol Exp Ther 350: 657–664.
32. Hediger M., Rhoads D., (1994) Molecular physiology of sodium-glucose cotransporters. Physiol Rev 74: 993–1026.
33. Heise T., Seewaldt-Becker E., Macha S., Hantel S., Pinnetti S., Seman L.. (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 15: 613–621.
34. Henry R., Rosenstock J., Edelman S., Mudaliar S., Chalamandaris A., Kasichayanula S.. (2015) Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double- blind, placebo-controlled pilot study. Diabetes Care 38(3): 412–419.
35. Holian J., Qi W., Kelly D., Zhang Y., Mreich E., Pollock C.. (2008) Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells. Am J Physiol Renal Physiol 295: F1388–F1396.
36. Hostetter T., Rennke H., Brenner B., (1982) The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72: 375–380.
37. Hostetter T., Troy J., Brenner B., (1981) Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19: 410–415.
38. Hussey E., Clark R., Amin D., Kipnes M., O’Connor-Semmes R., O’Driscoll E.. (2010) Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 50: 623–635.
39. James W., (2008) The fundamental drivers of the obesity epidemic. Obes Rev 9(Suppl. 1): 6–13.
40. Jerums G., Premaratne E., Panagiotopoulos S., MacIsaac R., (2010) The clinical significance of hyperfiltration in diabetes. Diabetologia 53: 2093–2104.
41. ™ (Canagliflozin) approved in the European Union for treatment of adults with type 2 diabetes. Available at: http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=809160. (accessed 7 July 2014).
42. Johnson D., Saunders H., Brew B., Poronnik P., Cook D., Field M.. (1998) TGFbeta 1 dissociates human proximal tubule cell growth and Na(+)-H+ exchange activity. Kidney Int 53: 1601–1607.
43. Kaku K., Watada H., Iwamoto Y., Utsunomiya K., Terauchi Y., Tobe K.. (2014) Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 13: 1–15.
44. Kohan D., Fioretto P., Tang W., List J., (2014) Long-term study of patients with type 2 diabetesT2DM and moderate renal impairment shows that dapagliflozin reduces weigh and blood pressure but does not improve glycemic control. Kidney Int 85: 962–971.
45. Kovacs C., Seshiah V., Swallow R., Jones R., Rattunde H., Woerle H.. (2013) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16(2): 147–158.
46. Kramer H., Molitch M., (2005) Screening for kidney disease in adults with diabetes. Diabetes Care 28: 1813–1816.
47. Lamos E., Younk L., Davis S., (2014) Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs 23: 875–882.
48. Liang Y., Arakawa K., Ueta K., Matsushita Y., Kuriyama C., Martin T.. (2012) Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7: e30555.
49. Lin H., Tseng C., (2014) A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrin 2014: 719578.
50. Nainggolan L., (2014) Ipragliflozin (Suglat) first of new diabetes drug class in Japan. Medscape Medical News. Available at: http://www.medscape.com/viewarticle/819447 (accessed 7 July 2014).
51. List J., Woo V., Morales E., Tang W., Fiedorek F., (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650–657.
52. Macha S., Mattheus M., Halabi A., Pinnetti S., Woerle H., Broedl U., (2014) Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 16: 215–222.
53. Magee G., Bilous R., Cardwell C., Hunter S., Kee F., Fogarty D., (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52: 691–697.
54. Majewski C., Bakris G., (2015) Blood pressure reduction: an added benefit of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care 38: 429–430.
55. Mark M., Vallon V., Hugo C., Roman R., Mayoux E., (2014) Albuminuria, the sentinel marker of renal failure, is consistently decreased with empagliflozin in several preclinical models of diabetic nephropathy. EASD Virtual Meeting. ePoster #824.
56. Markaham A., Elkinson S., (2014) Luseogliflozin: first global approval. Drugs 74: 945–950. doi:10.1007/s40265-014-0230-8.
57. Mechcatie E., (2014) FDA approves empagliflozin for adults with type 2 diabetes. Clinical Endocrinology News. Available at: http://www.clinicalendocrinologynews.com/home/article/fda-approves-empagliflozin-for-adults-with-type-2-diabetes/e8e500442424cf39148f889d6fe6b16c.html (accessed 2 March 2016).
58. Merck. (2015) Merck pipeline. Available at: http://www.merck.com/research/pipeline/home.html (accessed 2 March 2016, updated 31 October 2015).
59. Misra M., (2012) SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus: review. J Pharm Pharmacol 65: 317–327.
60. Nagata T., Fukuzawa T., Takeda M., Fukazawa M., Mori T., Nihei T.. (2013) Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170: 519–531.
61. Nauck M., Del Prato S., Meier J., Duran- Garcia S., Rohwedder K., Elze M.. (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34: 2015–2022.
62. Novikov A., Vallon V., (2015) Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens 24: 1–9.
63. Nyirjesy P., Zhao Y., Ways K., Usiskin K., (2012) Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 28: 1173–1178.
64. Oemar B., Byrd D., Brodehl J., (1987) Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clin Nephrol 27: 156–160.
65. Oku A., Ueta K., Arakawa K., Ishihara T., Nawano M., Kuronuma Y.. (1999) T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48: 1794–1800.
66. Oliva R., Bakris G., (2014) Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 8: 330–339.
67. Panchapakesan U., Pegg K., Gross S., Komala M., Mudaliar H., Forbes J.. (2013) Effects of SGLT2 inhibition in human kidney proximal tubular cells renoprotection in diabetic nephropathy? Plos One 8: e54442.
68. Panchapakesan U., Pollock C., Chen X, (2004) The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. Am J Physiol Renal Physiol 287: F528–F534.
69. Panchapakesan U., Sumual S., Pollock C., Chen X., (2005) PPAR-gamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 289: F1153–F1158.
70. Poole R., Prossler J., (2014) Tofogliflozin: first global approval. Drugs 74: 939–944.
71. Ptaszynska A., Cohen S., Messing E., Reilly T., Johnsson E., Johnsson K., (2015) Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’. Diabetes Ther 6: 357–375.
72. Qi W., Chen X., Holian J., Mreich E., Twigg S., Gilbert R.. (2006) Transforming growth factor-beta1 differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells. Am J Physiol Renal Physiol 291: F1070–F1077.
73. Qi W., Twigg S., Chen X., Polhill T., Poronnik P., Gilbert R.. (2005) Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol 288: F800–F809.
74. Rahmoune H., Thompson P., Ward J., Smith C., Hong G., Brown J., (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non–insulin-dependent diabetes. Diabetes 54: 3427–3434.
75. Reilly T., Graziano M., Janovitz E., Dorr T., Fairchild C., Lee F.. (2014) Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther 5: 73–96.
76. Rosenstock J., Aggarwal N., Polidori D., Zhao Y., Arbit D., Usiskin K.. (2012) Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35: 1232–1238.
77. Rosenstock J., Seman L., Jelaska A., Hantel S., Pinnetti S., Hach T.. (2013) Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 15: 1154–1160.
78. Rossetti L., Shulman G., Zawalich W., DeFronzo R., (1987a) Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80: 1037–1044.
79. Rossetti L., Smith D., Shulman G., Papachristou D., DeFronzo R., (1987b) Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79: 1510–1515.
80. Ruggenenti P., Porrini E., Gaspari F., Motterlini N., Cannata A., Carrara F.. (2012) Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 35: 2061–2068.
81. Santer R., Calado J., (2010) Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target: In-depth review. Clin J Am Soc Nephrol 5: 133–141.
82. Sarashina A., Koiwai K., Seman L., Yamamura N., Tanigughi A., Negishi T.. (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 28: 213–219.
83. Sasson A., Cherney D., (2012) Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes 3: 1–6.
84. Scheen A., (2014) Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 53: 213–225.
85. Scholl-Burgi S., Santer R., Ehrich J., (2004) Long-term outcome of renal glucosuria type 0: The original patient and his natural history. Nephrol Dial Transplant 19: 2394–2396.
86. Škrtić M., Yang G., Perkins B., Soleymanlou N., Lytvyn Y., Eynatten M.. (2014) Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57: 2599–2602.
87. Sochett E., Cherney D., Curtis J., Dekker M., Scholey J., Miller J., (2006) Impact of rennin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol 17: 1703–1709.
88. Starke A., Grundy S., McGarry J., Unger R., (1985) Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin deficient dogs: implications for human diabetes. Proc Natl Acad Sci USA 82: 1544–1546.
89. Stenlof K., Cefalu W., Kim K., Alba M., Usiskin K., Tong C.. (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15: 372–382.
90. Strojek K., Yoon K., Hruba V., Elze M., Langkilde A., Parikh S., (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13: 928–938.
91. Taylor S., Blau J., Rother K., (2015) SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100: 2849–2852.
92. Tervaert T., Mooyaart A., Amann K., Cohen A., Cook H., Drachenberg C.. (2010) Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21: 556–563.
93. Tikkanen I., Narko K., Zeller C., Green A., Salsali A., Broedl U.. (2015) Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38: 420–428.
94. Tirmenstein M., Dorr T., Janovitz E., Hagan D., Abell L., Onorato J.. (2013) Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor. Int J Toxicol 32: 336–350.
95. Turner R., Moran A., (1982a) Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Physiol Renal Fluid Electrolyte Physiol 242: F406–F414.
96. Turner R., Moran A., (1982b) Further studies of proximal tubular brush border membrane D-glucose transport heterogeneity. J Membr Biol 70: 37–45.
97. United Stated Food and Drug Administration (2011) Dapagliflozin. Background document [database on the Internet]. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM449865.pdf.
98. United States Food and Drug Administration (2013) FDA approves Invokana to treat type 2 diabetes. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm345848.htm (accessed 7 July 2014).
99. United States Food and Drug Administration (2014) FDA approves Farxiga to treat type 2 diabetes. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm (accessed 7 July 2014).
100. United States Food and Drug Administration Advisory Committee (2013) FDA briefing document. NDA 204042. Invokana (canagliflozin) Tablets. Applicant: Janssen Pharmaceuticals, Inc. Available at:www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf (accessed 5 May 2013).
101. Vallon V., Gerasimova M., Rose M., Masuda T., Satriano J., Mayoux E.. (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice. Am J Physiol Renal Physiol 306: F194–F204.
102. Vallon V., Platt K., Gunard R., Schroth J., Whaley J., Thomson S.. (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104–112.
103. Vallon V., Richter K., Blantz R., Thomson S., Osswald H., (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10: 2569–2576.
104. Veltkamp S., Kadokura T., Krauwinkel W., Smulders R., (2011) Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig 31: 839–851.
105. Vick H., Diedrich D., Baumann K., (1973) Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am J Physiol 224: 552–557.
106. Wanner C., Inzucchi S., Lachin J., Fitchett D., Eynatten M., Mattheus M.. (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323–334.
107. White J., (2010) Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition. Clin Diabetes 28: 5–10.
108. Wilding J., Ferrannini E., Fonseca V., Wilpshaar W., Dhanjal P., Houzer A., (2013) Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 15: 403–409.
109. Wilding J., Norwood P., T’joen C., Bastien A., List J., Fiedorek F., (2009) A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32: 1656–1662.
110. o 312. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/ (accessed 18 October 2016).
111. World Health Organization (2016) Diabetes fact sheet No 138. Available at: http://www.who.int/mediacentre/factsheets/fs138/en/ (accessed 18 October 2016).
112. Wright E., Hirayama B., Loo D., (2007) Active sugar transport in health and disease. J Int Med 261: 32–43.
113. Wright E., Hirayama B., Loo D., Turk E., Hager K., (1994) Intestinal sugar transport. In: L. Johnson (Ed.), Physiology of Gastrointestinal Tract (3rd ed.; pp. 1751–1772). New York, NY: Raven Press.
114. Wright E., Turc E., (2004) The sodium/glucose cotransport family SLC5. Pflugers Arch 447: 510–518.
115. Wright E., Loo D., Hirayama B., (2011) Biology of human sodium glucose transporters. Physiol Rev 91: 733–794.
116. Wu J., Foote C., Blomster J., Toyama T., Perkovic V., Sundström J.. (2016) Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4: 411–419. DOI:10.1016/S2213–8587(16)00052–8.
117. Yahoo Finance (2014) Islet sciences to acquire BHV pharma and phase 2 SGLT2 inhibitor remogliflozin etabonate indicated for T2DM and NASH. Available at: http://finance.yahoo.com/news/islet-sciences-acquire-bhv-pharma-131500341.html (accessed 2 March 2016).
118. Yale J., Bakris G., Cariou B., Yue D., David- Neto E., Xi L.. (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15: 463–473.
119. Younis F., Abassi Z., Mayoux E., Hollander K., Rath-Wolfson L., Rosenthal T., (2014) Empagliflozin, a selective SGLT2 inhibitor, ameliorated hyperglycaemia and insulin resistance, while preserving the integrity of pancreas and kidney in CRDH rats. EASD Virtual Meeting. Abstract #801.
120. Zinman B., Wanner C., Lachin J., Fitchett D., Bluhmki E., Hantel S.. (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128.